Literature DB >> 25795439

(18)F-FDG-PET/CT findings in pancreatic metastasis.

Shengping Hu1, Jian Zhang2, Changjing Zuo3, Chao Cheng4, Qinghua Liu5, Gaofeng Sun6.   

Abstract

PURPOSE: This study aimed to evaluate the fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) findings and pattern of FDG uptake in pancreatic metastases.
MATERIALS AND METHODS: A total of 19 consecutive patients (26 lesions) with histologically or clinically confirmed pancreatic metastases who had undergone (18)F-FDG-PET/CT were enrolled in this retrospective study. Among the 19 patients, 14 patients underwent abdominal contrast-enhanced CT (ceCT). The location, size and FDG uptake patterns of the pancreatic lesions were recorded. Metabolic activity by means of maximum standardised uptake value (SUVmax) was measured by drawing regions of interest at the site of pancreatic lesions. Twenty pancreatic cancer patients were included in this study as comparative data analysis. The difference of SUVmax between pancreatic metastases and primary pancreatic cancer were compared using the Mann-Whitney U test. P < 0.05 was considered significant.
RESULTS: Three different patterns of FDG uptake could be distinguished in the pancreatic metastatic lesions, including focal nodule or mass, multiple foci and segmental lesion with high FDG uptake. The average SUVmax in pancreatic metastases was 7.8 ± 6.9 versus 7.4 ± 3.9 in primary pancreatic cancer (P = 0.987 > 0.05). Four intrapancreatic isodense nodules in three patients were undetected on ceCT.
CONCLUSION: The described patterns of FDG uptake findings may be helpful for a better characterisation of pancreatic metastases although semiquantitative analysis using SUVmax could not be used as a criterion for differentiating pancreatic metastases from primary pancreatic cancer. FDG-PET/CT has also an advantage in detecting unsuspected pancreatic metastases which cannot be detected by ceCT imaging. Thus, it is a useful adjunct to the described features on CT.

Entities:  

Keywords:  18F-FDG-PET/CT; Contrast-enhanced CT; Pancreas; Pancreatic metastasis

Mesh:

Substances:

Year:  2015        PMID: 25795439     DOI: 10.1007/s11547-014-0473-1

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  23 in total

1.  Pancreatic metastases: CT assessment.

Authors:  F Ferrozzi; D Bova; F Campodonico; F D Chiara; A Passari; P Bassi
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

2.  Extrahepatic biliary obstruction due to a solitary pancreatic metastasis of squamous cell lung carcinoma. Case report.

Authors:  Nikolaos Liratzopoulos; Eleni I Efremidou; Michalis S Papageorgiou; Konstantinos Romanidis; Georgios J Minopoulos; Konstantinos J Manolas
Journal:  J Gastrointestin Liver Dis       Date:  2006-03       Impact factor: 2.008

3.  Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma.

Authors:  Thomas Borschitz; Waltraud Eichhorn; Christian Fottner; Torsten Hansen; Arno Schad; Simin Schadmand-Fischer; Matthias M Weber; Mathias Schreckenberger; Hauke Lang; Thomas J Musholt
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

4.  Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer.

Authors:  Winnie Wing-Chuen Lam; Kelvin Siu-Hoong Loke; Hoi Yin Loi; Ajit Kumar Padhy
Journal:  Clin Nucl Med       Date:  2011-06       Impact factor: 7.794

Review 5.  PET/CT in the evaluation of childhood sarcomas.

Authors:  M Beth McCarville; Ryan Christie; Najat C Daw; Sheri L Spunt; Sue C Kaste
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

6.  Multidetector computed tomography in the study of pancreatic metastases.

Authors:  G Angelelli; M Mancini; P Pignataro; P Pedote; A Scardapane
Journal:  Radiol Med       Date:  2011-10-21       Impact factor: 3.469

7.  FDG-PET/CT findings of autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Kensuke Takum; Hajime Anjiki; Naoto Egawa; Masanao Kurata; Goro Honda; Koji Tsuruta
Journal:  Hepatogastroenterology       Date:  2010 May-Jun

8.  Renal cell carcinoma metastases to the pancreas: value of arterial phase imaging at MDCT.

Authors:  Michael T Corwin; Ramit Lamba; Machelle Wilson; John P McGahan
Journal:  Acta Radiol       Date:  2013-01-16       Impact factor: 1.990

9.  Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging.

Authors:  Priyanka Jha; Andreas M J Frölich; Beth McCarville; Oscar M Navarro; Paul Babyn; Robert Goldsby; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2010-02-24

10.  Hypermetabolic lesions of the pancreas on FDG PET/CT.

Authors:  Aisheng Dong; Hui Dong; Ling Zhang; Changjing Zuo
Journal:  Clin Nucl Med       Date:  2013-09       Impact factor: 7.794

View more
  5 in total

Review 1.  Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Domenico Tamburrino; Deniece Riviere; Mohammad Yaghoobi; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2016-09-15

2.  Pancreatic FDG uptake on follow-up PET/CT in patients with cancer.

Authors:  Hitomi Iwasa; Yoriko Murata; Miki Nishimori; Kana Miyatake; Shino Kohsaki; Naoya Hayashi; Naoki Akagi; Takuhiro Kohsaki; Kazushige Uchida; Takuji Yamagami
Journal:  Oncol Lett       Date:  2021-02-09       Impact factor: 2.967

Review 3.  Metastatic pancreatic cancer: Mechanisms and detection (Review).

Authors:  Xiangling Chen; Fangfang Liu; Qingping Xue; Xiechuan Weng; Fan Xu
Journal:  Oncol Rep       Date:  2021-09-09       Impact factor: 3.906

Review 4.  Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer.

Authors:  Takeshi Okamoto
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

5.  Laparoscopic pancreaticoduodenectomy for metastatic pancreatic melanoma: A case report.

Authors:  Xueqing Liu; Feng Feng; Tianyang Wang; Jianzhang Qin; Xiangyan Yin; Guiqing Meng; Changqing Yan; Zhongqiang Xing; Jiayue Duan; Chen Liu; Jianhua Liu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.